Deakin home > Deakin University Library > Deakin Research Online > The global biopharma industry and the rise of Indian drug multinationals: implication for Australian generics policy

The global biopharma industry and the rise of Indian drug multinationals: implication for Australian generics policy

Lofgren, Hans 2007, The global biopharma industry and the rise of Indian drug multinationals: implication for Australian generics policy, Australia and New Zealand health policy, vol. 4, no. 10, pp. 1-7.

Attached Files (Some files may be inaccessible until you login with your Deakin Research Online credentials)
Name Description MIMEType Size Downloads

Title The global biopharma industry and the rise of Indian drug multinationals: implication for Australian generics policy
Author(s) Lofgren, Hans
Journal name Australia and New Zealand health policy
Volume number 4
Issue number 10
Start page 1
End page 7
Publisher BioMed Central Ltd.
Place of publication London, England
Publication date 2007-06-01
ISSN 1743-8462
Summary This article provides a synopsis of the new dynamics of the global biopharma industry. The emergence of global generics companies with capabilities approximating those of 'big pharma' has accelerated the blurring of boundaries between the innovator and generics sectors. Biotechnology-based products form a large and growing segment of prescription drug markets and regulatory pathways for biogenerics are imminent. Indian biopharma multinationals with large-scale efficient manufacturing plants and growing R&D capabilities are now major suppliers of Active Pharmaceutical Ingredients (APIs) and generic drugs across both developed and developing countries. In response to generic competition, innovator companies employ a range of life cycle management techniques, including the launch of 'authorised generics'. The generics segment in Australia will see high growth rates in coming years but the prospect for local manufacturing is bleak. The availability of cheap generics in international markets has put pressure on Pharmaceutical Benefits Scheme (PBS) pricing arrangements, and a new policy direction was announced in November 2006. Lower generics prices will have a negative impact on some incumbent suppliers but industrial renewal policies for the medicines industry in Australia are better focused on higher value R&D activities and niche manufacturing of sophisticated products.
Language eng
Field of Research 169999 Studies in Human Society not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2007, Löfgren
Persistent URL http://hdl.handle.net/10536/DRO/DU:30007794

Document type: Journal Article
Collection: School of International and Political Studies
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in Deakin Research Online is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 5 times in Scopus
Access Statistics: 355 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 29 Sep 2008, 08:56:11 EST